Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Accounts Payables (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Accounts Payables readings, the most recent being $2.9 million for Q1 2026.

  • Quarterly Accounts Payables fell 43.9% to $2.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2026, down 43.9% year-over-year, with the annual reading at $3.8 million for FY2025, 147.03% up from the prior year.
  • Accounts Payables hit $2.9 million in Q1 2026 for Oric Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.2 million in Q1 2025 and bottomed at $888000.0 in Q1 2022.
  • Average Accounts Payables over 5 years is $2.6 million, with a median of $2.9 million recorded in 2026.
  • The largest annual shift saw Accounts Payables surged 265.63% in 2022 before it plummeted 43.9% in 2026.
  • Oric Pharmaceuticals' Accounts Payables stood at $1.3 million in 2022, then decreased by 28.48% to $944000.0 in 2023, then soared by 63.98% to $1.5 million in 2024, then surged by 147.03% to $3.8 million in 2025, then fell by 24.29% to $2.9 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Accounts Payables are $2.9 million (Q1 2026), $3.8 million (Q4 2025), and $2.9 million (Q3 2025).